Media coverage about Foamix Pharmaceuticals (NASDAQ:FOMX) has trended somewhat negative on Friday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a coverage optimism score of -0.03 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 46.0109473273664 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Foamix Pharmaceuticals (NASDAQ:FOMX) opened at 6.795 on Friday. The company’s 50 day moving average price is $5.50 and its 200 day moving average price is $4.90. Foamix Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $11.27. The stock’s market capitalization is $254.31 million.
Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.05). The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $1.50 million. Foamix Pharmaceuticals had a negative return on equity of 39.20% and a negative net margin of 823.74%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.27) earnings per share. Equities analysts anticipate that Foamix Pharmaceuticals will post ($1.53) earnings per share for the current fiscal year.
FOMX has been the subject of several research analyst reports. Zacks Investment Research downgraded Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Credit Suisse Group reaffirmed a “buy” rating and set a $9.00 target price on shares of Foamix Pharmaceuticals in a research note on Wednesday, July 19th. Finally, HC Wainwright initiated coverage on Foamix Pharmaceuticals in a research note on Thursday, August 24th. They set a “buy” rating and a $12.00 target price for the company.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.com-unik.info/2017/10/13/foamix-pharmaceuticals-fomx-earns-daily-coverage-optimism-score-of-0-03.html.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
What are top analysts saying about Foamix Pharmaceuticals Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Foamix Pharmaceuticals Ltd. and related companies.